Adolescent Depression | An Adaptive Treatment Strategy for Adolescent Depression-Continuation
Adolescent Depression research study
What is the primary objective of this study?
The purpose of the study is: 1. To find out how long teenagers getting talk therapy (interpersonal psychotherapy) for depression should get therapy before the therapist decides whether or not the teenager is improving enough, and 2. To compare two ways of providing treatment to teenagers who have not improved enough.
Who is eligible to participate?
Inclusion Criteria: - Adolescent meets DSM-IV-TR criteria for a diagnosis of Major Depressive Disorder, Dysthymia, or Depressive Disorder NOS; demonstrate symptoms of depression (CDRS-R > 35); and demonstrate impairment in general functioning (CGAS < 65). - Adolescents and parents must be English-speaking Exclusion Criteria: - Adolescent meets criteria for a diagnosis of Schizophrenia, Bipolar Disorder, Psychosis, Substance Abuse, OCD, Conduct Disorder, Eating Disorder, PDD, or Mental Retardation. - Depressed adolescents who are actively suicidal with a plan and/or intent - Adolescent that are already receiving treatment for depression or if they are taking medication for a psychiatric diagnosis other than ADHD. Depressed adolescents with a comorbid diagnosis of ADHD who are on a stable dose of stimulant medication (> 3 months) will be eligible to participate in the studies. - Adolescent that have already received an adequate trial of IPT-A or fluoxetine. - Female adolescents who are pregnant, breastfeeding, or having unprotected sexual intercourse.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:FluoxetineAdolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter.
Behavioral:Interpersonal PsychotherapyAdolescent randomized to an increase in therapy (4 extra therapy sessions)
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Interpersonal PsychotherapyType of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.
FluoxetineThe dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. The medication will be taken as a daily pill.
Start Date: June 2012
Completed Date: October 1, 2018
Phase: Phase 1/Phase 2
Primary Outcome: K-SADS-PL - baseline; change from baseline in KSADS at week 16 and 32
Study sponsors, principal investigator, and references
Principal Investigator: Meredith Gunlicks-Stoessel, PhD
Lead Sponsor: University of Minnesota - Clinical and Translational Science Institute
Collaborator: University of Minnesota, MN